Source:http://linkedlifedata.com/resource/pubmed/id/18702958
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0021760,
umls-concept:C0028754,
umls-concept:C0036536,
umls-concept:C0036537,
umls-concept:C0061355,
umls-concept:C0066535,
umls-concept:C0205177,
umls-concept:C0376674,
umls-concept:C0442805,
umls-concept:C0681850,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C2349001,
umls-concept:C2349975,
umls-concept:C2697811
|
| pubmed:issue |
9
|
| pubmed:dateCreated |
2008-8-15
|
| pubmed:abstractText |
Visceral obesity and insulin resistance are regarded as risk factors for atherosclerosis. Epidemiologic studies have demonstrated long-term anti-atherosclerotic effects with administration of alpha-glucosidase inhibitors. Alpha-glucosidase inhibitors also have been reported to enhance glucagon-like peptide 1 (GLP-1) secretion. We compared the postprandial effects of a single administration of miglitol and acarbose on glucose and lipid metabolism, on insulin requirement, on GLP-1 secretion, and on inflammatory and endothelial markers in viscerally obese subjects. Twenty-four viscerally obese subjects with relative insulin resistance participated in this study. Subjects were given a single dose of miglitol (50 mg), acarbose (100 mg), or placebo blindly and randomly before a meal in a crossover design. The meal loads after drug administration were tested 3 times within 2 weeks. We measured glucose, insulin, lipids, lipoprotein lipase, interleukin 6, intracellular adhesion molecule 1, vascular cell adhesion molecule 1, and active GLP-1 at before and various minutes after the meal. Single administration of both alpha-glucosidase inhibitors had several beneficial effects in improving postprandial hyperglycemia and reducing postprandial insulin requirement approximately 25% of placebo without adversely affecting lipid profiles. Although lipoprotein lipase levels within 2 hours after the meal did not show differences among miglitol, acarbose, and placebo administrations, miglitol significantly suppressed the increases in triglycerides, remnant-like particle triglycerides, and remnant-like particle cholesterol compared to acarbose and placebo in the early phase. Miglitol also significantly enhanced active GLP-1 secretion to a greater extent than acarbose (P < .01) and placebo (P < .001), and significantly suppressed the postprandial increase in interleukin 6 compared to placebo (P < .01). The results point to the potential suitability of miglitol as an anti-atherosclerotic effect in viscerally obese subjects, in preference to acarbose. Further studies are needed to elucidate the long-term effects on enhanced GLP-1 secretion and anti-atherosclerosis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Deoxynojirimycin,
http://linkedlifedata.com/resource/pubmed/chemical/Acarbose,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon-Like Peptide 1,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Lipids,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoprotein Lipase,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Cell Adhesion Molecule-1,
http://linkedlifedata.com/resource/pubmed/chemical/miglitol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1532-8600
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
57
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1299-306
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:18702958-1-Deoxynojirimycin,
pubmed-meshheading:18702958-Acarbose,
pubmed-meshheading:18702958-Adult,
pubmed-meshheading:18702958-Blood Glucose,
pubmed-meshheading:18702958-Cross-Over Studies,
pubmed-meshheading:18702958-Enzyme Inhibitors,
pubmed-meshheading:18702958-Female,
pubmed-meshheading:18702958-Glucagon-Like Peptide 1,
pubmed-meshheading:18702958-Humans,
pubmed-meshheading:18702958-Insulin,
pubmed-meshheading:18702958-Intercellular Adhesion Molecule-1,
pubmed-meshheading:18702958-Interleukin-6,
pubmed-meshheading:18702958-Lipids,
pubmed-meshheading:18702958-Lipoprotein Lipase,
pubmed-meshheading:18702958-Male,
pubmed-meshheading:18702958-Middle Aged,
pubmed-meshheading:18702958-Obesity,
pubmed-meshheading:18702958-Postprandial Period,
pubmed-meshheading:18702958-Single-Blind Method,
pubmed-meshheading:18702958-Vascular Cell Adhesion Molecule-1,
pubmed-meshheading:18702958-Viscera
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
|
| pubmed:affiliation |
Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial
|